CTLA4 and neoplasm: Anti-programmed cell death protein 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) and anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) are the most commonly used tumor immunotherapy approaches (4).